A Fujioka

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

Tetsuhiko Shirasaka, K Nakano, T Takechi et al. · PubMed · 1996 · 370 citations

Medicine, Oncology, Pharmacology +9

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

M Fukushima, Hirofumi Satake, Junji Uchida et al. · International Journal of Oncology · 1998 · 105 citations

Medicine, Oncology, Pharmacology +14

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells

Teiji Takechi, A Fujioka, Eiji Matsushima et al. · European Journal of Cancer · 2002 · 86 citations

Medicine, Oncology, Pharmacology +14

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

Masakazu Fukushima, A Fujioka, Junji Uchida et al. · European Journal of Cancer · 2001 · 79 citations

Medicine, Oncology, Pharmacology +16

Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells

Teiji Takechi, J Uchida, A Fujioka et al. · International Journal of Oncology · 1997 · 34 citations

Medicine, Oncology, Pharmacology +14